A preliminary study by the same researchers found terazosin, an α-1 adrenergic receptor antagonist commonly used to regulate abnormal prostatic hyperplasia, found that the drug and Closely linked α-1 adrenergic receptor antagonists, doxazosin and alfuzosin, bind and promote cells. energy levels.
In addition, these drugs have been shown to inhibit or slow the progression of PD in animal models and in men with PD, from the Truven Health Analytics MarketScan database in the United States, which had been taking 1 of the medications.
Attempting to further examine the possible association in men, the study authors evaluated 2 patient data sets, the Truven database from January 2001 to December 2017 and national health records in the Denmark from January 1996 to December 2017. Researchers compared men without PD who started a new terazosin. / doxazosin / alfuzosin therapy or tamsulosin therapy, a similar symptomatic drug used to treat an enlarged prostate but which does not increase cellular energy levels.
Magnitude score – male pairs of terazosin / doxazosin / alfuzosin users and tamsulosin users in Danish records (N = 52,365; average; [SD] age, 67.9 [10.4] years) and Truven database (N = 94,883; mean [SD] age, 63.8 [11.1] year) followed 1 year after treatment. HR was used to differentiate between the two treatment groups in the development of tested PD or using specific PD medications.
In evaluating both data set groups, patients who underwent terazosin / doxazosin / alfuzosin had a lower risk of developing PD, as patients had an HR of 0.88 (95% CI, 0.81–0.98). in the Danish cohort and patients in the Truven cohort. had an HR of 0.63 (95% CI, 0.58–0.69).
“Despite the comparative differences in the structure of the health care system and population, we found a similar protective effect in both countries,” said study author Jacob Simmering, PhD, associate professor of internal medicine at the University of Iowa, in a statement.
In addition, a dose-response association was found with short-, medium-, and long-term use of terazosin / doxazosin / alfuzosin: Long-term users were associated with the lowest risk for PD improved of those observed in the two Danish cohorts (short: HR, 0.95; 95% CI, 0.84–1.07; medium: HR, 0.88; 95% CI, 0.77–1.01; long: HR, 0.79; 95% CI, 0.66–0.95) and Truven cohort (short: HR, 0.70; 95% CI, 0.64–0.76; medium: HR, 0.58; 95% CI, 0.52–0.64; long: HR, 0.46; 95% CI, 0.36– 0.57).
“A replica of what has been found in an international body is powerful evidence demonstrating causal impact,” Simmering concluded. “If these results are confirmed by further study, especially a randomized clinical trial, terazosin may provide neuroprotection and may prevent – and not just regulate – PD. ”
Information
Simmering JE, Welsh MJ, Liu L, Narayanan NS, Pottegård A. Association of α-1 inhibitors that promote glycolysis with a risk of developing Parkinson’s disease. JAMA Neurol. Published online 1 February 2020. doi: 10.1001 / jamaneurol.2020.5157